Product How it works Pricing Blog FAQ About Contact
Inhibikase Therapeutics

Inhibikase Therapeutics (NASDAQ: IKT) net income

Inhibikase Therapeutics reported a net loss of $48.3m for fiscal 2025; in fiscal 2024 it reported a net loss of $27.5m. Earnings per share were −$0.49.

Inhibikase Therapeutics's best year of the last 6 was fiscal 2020. It reported a loss in 6 of those 6 years.

Net income, in millions of US dollars-2.82020-14.82021-18.12022-19.02023-27.52024-48.32025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Net income by fiscal year

Fiscal yearNet incomeChangeNet marginEarnings per share
2025−$48.3m——−$0.49
2024−$27.5m——−$1.16
2023−$19.0m—−7,304.7%−$3.57
2022−$18.1m—−14,625.9%−$0.72
2021−$14.8m—−476.9%−$0.81
2020−$2.8m—−407.7%—

The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Inhibikase Therapeutics net income compared with its sector

By net income for its latest fiscal year, Inhibikase Therapeutics ranks 252nd of the 501 US health care companies with a page on Celsmar.

RankCompanyNet incomeNet margin
250thPrecision Biosciences−$45.7m−133.4%
251stAnavex Life Sciences−$46.4m—
252ndInhibikase Therapeutics−$48.3m—
253rdShattuck Labs−$48.8m−4,880.9%
254thSepterna−$48.9m−106.4%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the net income of Inhibikase Therapeutics

How much did Inhibikase Therapeutics earn in fiscal 2025?
Inhibikase Therapeutics reported a net loss of $48.3m for fiscal 2025. In fiscal 2024 it reported a net loss of $27.5m.
What are the earnings per share of Inhibikase Therapeutics?
They were −$0.49 in fiscal 2025, compared with −$1.16 in fiscal 2024.
Where does Inhibikase Therapeutics rank in its sector by net income?
It ranks 252nd of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
Where do the figures for Inhibikase Therapeutics come from?
From the annual report (Form 10-K) that Inhibikase Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Inhibikase Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Inhibikase Therapeutics: the Inhibikase Therapeutics page · annual accounts · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.